Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

People lose weight via three primary methods: diet and exercise, weight loss surgery and GLP-1 weight loss drugs. The ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.

Users of Ozempic and other drugs are shunning items like energy drinks and salty snacks, research shows. But there are ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications. Learn why MCD stock is a Sell.

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Noom releases a significant update of its innovative GLP-1 companion to improve medication persistence and adherence while ...

Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

Data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of ...